Cited by 345Click Chemistry and ApplicationsComputational Drug Discovery MethodsEnzyme function and inhibition

The DOI matches its Crossref record; 126 of the 127 references it cites were found in a registry or an index.

Covalent inhibitors design and discovery.

De Cesco, Stephane, Kurian, Jerry, Dufresne, Caroline, Mittermaier, Anthony K., Moitessier, Nicolas·2017·European Journal of Medicinal Chemistry

DOI 10.1016/j.ejmech.2017.06.019

Open this paper in CoChat — free account

Abstract

In the history of therapeutics, covalent drugs occupy a very distinct category. While representing a significant fraction of the drugs on the market, very few have been deliberately designed to interact covalently with their biological target. In this review, the prevalence of covalent drugs will first be briefly covered, followed by an introduction to their mechanisms of action and more detailed discussions of their discovery and the development of safe and efficient covalent enzyme inhibitors. All stages of a drug discovery program will be covered, from target considerations to lead optimization, strategies to tune reactivity and computational methods. The goal of this article is to provide an overview of the field and to outline good practices that are needed for the proper assessment and development of covalent inhibitors as well as a good understanding of the potential and limitations of current computational methods for the design of covalent drugs.

Integrity signals

Registry

Crossref · 10.1016/j.ejmech.2017.06.019

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 4×
“In this example, a mutant of the receptor enhances the affinity for ATP (endogenous substrate of EGFR).”
BackgroundInfluential
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Identifying and Characterizing Binding Sites and Assessing Druggability
Halgren, T. A. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800324m · Cited by 1,808
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
Fleming, F. F., Yao, L., Ravikumar, P. C., Funk, L. A., & Shook, B. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100762r · Cited by 1,776
Quantitative reactivity profiling predicts functional cysteines in proteomes
Weerapana, E., Wang, C., Simon, G. M., Richter, F., Khare, S., Dillon, M. B. D., Bachovchin, D. A., Mowen, K., Baker, D., & Cravatt, B. F. (2010) · Nature · doi:10.1038/nature09472 · Cited by 1,684
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,635
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Activity-Based Protein Profiling: From Enzyme Chemistry to Proteomic Chemistry
Cravatt, B. F., Wright, A. T., & Kozarich, J. W. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.124125 · Cited by 1,270
Activity-based protein profiling: The serine hydrolases
Liu, Y., Patricelli, M. P., & Cravatt, B. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14694 · Cited by 1,143
Chemistry: Chemical con artists foil drug discovery
Baell, J. B., & Walters, M. A. (2014) · Nature · doi:10.1038/513481a · Cited by 1,048
Navigating chemical space for biology and medicine
Lipinski, C. A., & Hopkins, A. L. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,028
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
Fisher, J. F., Meroueh, S. O., & Mobashery, S. (2005) · Chemical Reviews · doi:10.1021/cr030102i · Cited by 914
The drug–target residence time model: a 10-year retrospective
Copeland, R. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.18 · Cited by 736
Natural products and drug discovery
Ji, H., Li, X., & Zhang, H. (2009) · EMBO Reports · doi:10.1038/embor.2009.12 · Cited by 664
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
Tummino, P. J., & Copeland, R. A. (2008) · Biochemistry · doi:10.1021/bi8002023 · Cited by 553
Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go
Moitessier, N., Englebienne, P., Lee, D., Lawandi, J., & Corbeil, C. R. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707515 · Cited by 514
Self-citation
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 505
The slow-binding and slow, tight-binding inhibition of enzyme-catalysed reactions
Morrison, J. F. (1982) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(82)90157-8 · Cited by 496
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Gauthier, J. Y., Chauret, N., Cromlish, W. A., Desmarais, S., Duong, L. T., Falgueyret, J., Kimmel, D. B., Lamontagne, S., Léger, S., LeRiche, T., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.047 · Cited by 479
Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring
Zhu, K., Borrelli, K. W., Greenwood, J. R., Day, T., Abel, R., Farid, R., & Harder, E. D. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500118s · Cited by 474
Boron Containing Compounds as Protease Inhibitors
Smoum, R., Rubinstein, A., Dembitsky, V. M., & Srebnik, M. (2012) · Chemical Reviews · doi:10.1021/cr608202m · Cited by 454
Drug–target residence time: critical information for lead optimization
Lu, H., & Tonge, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.176 · Cited by 440
Prolonged and tunable residence time using reversible covalent kinase inhibitors
Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A. R., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V. P., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 437
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole
Olbe, L. C., Carlsson, E. I., & Lindberg, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1010 · Cited by 428
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
Enzyme Inhibitor Discovery by Activity-Based Protein Profiling
Niphakis, M. J., & Cravatt, B. F. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035708 · Cited by 374
Discovery of Potent and Selective Covalent Inhibitors of JNK
Zhang, T., Iñesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.010 · Cited by 361
Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications
Trippier, P. C., & McGuigan, C. (2010) · MedChemComm · doi:10.1039/c0md00119h · Cited by 349
Application of the Theory of Diffusion-controlled Reactions to Enzyme Kinetics
Alberty, R., & Hammes, G. (1958) · The Journal of Physical Chemistry · doi:10.1021/j150560a005 · Cited by 338
Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors
Flanagan, M. E., Abramite, J. A., Anderson, D. P., AULABAUGH, A. E., Dahal, U. P., Gilbert, A. M., Li, C., Montgomery, J. I., Oppenheimer, S. R., Ryder, T. F., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501412a · Cited by 337
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Barf, T., & Kaptein, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003203 · Cited by 331
Mode of action of orlistat.
Guerciolini, R. (1997) · PubMed · Cited by 326
The mechanism of action of the antisecretory agent omeprazole
Lindberg, P., Nordberg, P., Alminger, T., BRAENDSTROEM, A., & Wallmark, B. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00158a001 · Cited by 306
FAF-Drugs3: a web server for compound property calculation and chemical library design
Lagorce, D., Spérandio, O., Baell, J. B., Miteva, M. A., & Villoutreix, B. O. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv353 · Cited by 285
Electrophilic natural products and their biological targets
Gersch, M., Kreuzer, J., & Sieber, S. A. (2012) · Natural Product Reports · doi:10.1039/c2np20012k · Cited by 282
Activity-based protein profiling for the functional annotation of enzymes
Barglow, K. T., & Cravatt, B. F. (2007) · Nature Methods · doi:10.1038/nmeth1092 · Cited by 281
Phantom PAINS: Problems with the Utility of Alerts for P an- A ssay IN terference Compound S
Capuzzi, S. J., Muratov, E. N., & Tropsha, A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00465 · Cited by 276
Covalent docking of large libraries for the discovery of chemical probes
London, N., Miller, R. M., Krishnan, S., Uchida, K., Irwin, J. J., Eidam, O., Gibold, L., Cimermančič, P., Bonnet, R., Shoichet, B. K., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1666 · Cited by 274
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
Kwong, A. D., Kauffman, R. S., Hurter, P. N., & Mueller, P. (2011) · Nature Biotechnology · doi:10.1038/nbt.2020 · Cited by 273
Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and Computational Analysis
Krishnan, S., Miller, R. M., Tian, B., Mullins, R. D., Jacobson, M. P., & Taunton, J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505194w · Cited by 270
Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin
Skarzynski, T. J., Mistry, A., Wonacott, A. J., Hutchinson, S. E., Kelly, V. A., & Duncan, K. (1996) · Structure · doi:10.1016/s0969-2126(96)00153-0 · Cited by 266
Chemical Strategies for Activity‐Based Proteomics
Speers, A. E., & Cravatt, B. F. (2003) · ChemBioChem · doi:10.1002/cbic.200300721 · Cited by 259
Protein‐Reactive Natural Products
DRAHL, C., Cravatt, B. F., & Sorensen, E. J. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200500900 · Cited by 251
Mechanistic Basis of Enzyme-Targeted Drugs
Robertson, J. G. (2005) · Biochemistry · doi:10.1021/bi050247e · Cited by 247
Covalent docking using autodock: two-point attractor and flexible side chain methods.
Bianco, G., Forli, S., Goodsell, D. S., & Olson, A. J. (2016) · Protein Science · doi:10.1002/pro.2733 · Cited by 246
Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes
Bachovchin, D. A., Brown, S. J., Rosen, H., & Cravatt, B. F. (2009) · Nature Biotechnology · doi:10.1038/nbt.1531 · Cited by 245
Structural Basis of Proline-Specific Exopeptidase Activity as Observed in Human Dipeptidyl Peptidase-IV
Thoma, R., Löffler, B., Stihle, M., Huber, W., Ruf, A., & Hennig, M. (2003) · Structure · doi:10.1016/s0969-2126(03)00160-6 · Cited by 240
Activity-Based Proteome Profiling of Potential Cellular Targets of Orlistat − An FDA-Approved Drug with Anti-Tumor Activities
Yang, P., Liu, K., Ngai, M. H., Lear, M. J., Wenk, M. R., & Yao, S. Q. (2009) · Journal of the American Chemical Society · doi:10.1021/ja907716f · Cited by 235
The topology of drug–target interaction networks: implicit dependence on drug properties and target families
Mestres, J., Gregori‐Puigjané, E., Valverde, S., & Solé, R. V. (2009) · Molecular BioSystems · doi:10.1039/b905821b · Cited by 213
Epoxomicin, a new antitumor agent of microbial origin.
Hanada, M., Sugawara, K., KANETA, K., TODA, S., Nishiyama, Y., Tomita, K., Yamamoto, H., KONISHI, M., & OKI, T. (1992) · The Journal of Antibiotics · doi:10.7164/antibiotics.45.1746 · Cited by 213
The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety
Copeland, R. A. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003677725 · Cited by 210
Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies
Hall, A. G., & Tilby, M. J. (1992) · Blood Reviews · doi:10.1016/0268-960x(92)90028-o · Cited by 210
DOCKTITE—A Highly Versatile Step-by-Step Workflow for Covalent Docking and Virtual Screening in the Molecular Operating Environment
Scholz, C., Knorr, S., Hamacher, K., & Schmidt, B. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500681r · Cited by 209
Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270
Ding, Z., Kim, S., Dorsam, R. T., Jin, J., & Kunapuli, S. P. (2003) · Blood · doi:10.1182/blood-2002-10-3027 · Cited by 207
Pharmacological targeting of the pseudokinase Her3
Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1658 · Cited by 205
Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors
Leproult, É., Barluenga, S., Moras, D., Wurtz, J., & Winssinger, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101396q · Cited by 203
Beyond Picomolar Affinities: Quantitative Aspects of Noncovalent and Covalent Binding of Drugs to Proteins
Smith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193
kinITC: A New Method for Obtaining Joint Thermodynamic and Kinetic Data by Isothermal Titration Calorimetry
Burnouf, D., Ennifar, E., Guedich, S., Puffer, B., Hoffmann, G., Bec, G., Disdier, F., Baltzinger, M., & Dumas, P. (2011) · Journal of the American Chemical Society · doi:10.1021/ja209057d · Cited by 185
The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro
Gee, J. M. W., Harper, M. E., Hutcheson, I. R., Madden, T. A., Barrow, D., Knowlden, J. M., McClelland, R. A., Jordan, N., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2003-0705 · Cited by 170
Leptomycins A and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterization.
Hamamoto, T., Gunji, S., TSUJI, H., & Beppu, T. (1983) · The Journal of Antibiotics · doi:10.7164/antibiotics.36.639 · Cited by 168
Drug‐Target Residence Time—A Case for G Protein‐Coupled Receptors
Guo, D. M., Hillger, J. M., IJzerman, A. P., & Heitman, L. H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21307 · Cited by 167
De Novo Drug Design
Hartenfeller, M., & Schneider, G. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-839-3_12 · Cited by 165
Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values
Krippendorff, B., Neuhaus, R., Lienau, P., Reichel, A., & Huisinga, W. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109336751 · Cited by 160
Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
Kumalo, H., Bhakat, S., & Soliman, M. (2015) · Molecules · doi:10.3390/molecules20021984 · Cited by 158
Structure-Based Virtual Screening Approach for Discovery of Covalently Bound Ligands
Warshaviak, D. T., Golan, G., Borrelli, K. W., Zhu, K., & Kalid, O. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500175r · Cited by 156
The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
Seguin, F., Carvalho, M. A., Bastos, D. C., Agostini, M., Zecchin, K. G., Flores, M. P. A., Chudzinski-Tavassi, A. M., Coletta, R. D., & Graner, E. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.355 · Cited by 154
Natural Products and Drug Discovery
Demain, A. L., & Zhang, L. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-976-9_1 · Cited by 153
Biomolecular Interaction Analysis in Drug Discovery Using Surface Plasmon Resonance Technology
Huber, W., & Mueller, F. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778743600 · Cited by 151
A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds
Oballa, R. M., Truchon, J., Bayly, C. I., Chauret, N., Day, S., Crane, S. N., & Berthelette, C. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.044 · Cited by 150
Translating slow-binding inhibition kinetics into cellular and in vivo effects
Walkup, G. K., You, Z., Ross, P. L., Allen, E. K. H., Daryaee, F., Hale, M. R., O’Donnell, J. C., Ehmann, D. E., Schuck, V., Buurman, E. T., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1796 · Cited by 146
Evidence That the Fosfomycin Target Cys115 in UDP-N-acetylglucosamine Enolpyruvyl Transferase (MurA) Is Essential for Product Release
Eschenburg, S., Priestman, M. A., & Schönbrunn, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411325200 · Cited by 141
Prediction of Michael-Type Acceptor Reactivity toward Glutathione
Schwöbel, J. A. H., Wondrousch, D., Koleva, Y. K., Madden, J. C., Cronin, M., & Schüürmann, G. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100172x · Cited by 136
CovalentDock: Automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints
Ouyang, X., Zhou, S., Su, C. T. T., Ge, Z., Li, R., & Kwoh, C. K. (2013) · Journal of Computational Chemistry · doi:10.1002/jcc.23136 · Cited by 134
Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation
Metzler, W. J., Yanchunas, J., Weigelt, C. A., Kish, K., Klei, H. E., Xie, D., Zhang, Y., Corbett, M. J., Tamura, J. K., He, B., et al. (2008) · Protein Science · doi:10.1110/ps.073253208 · Cited by 132
The Fatty Acid Synthase Inhibitor Orlistat Reduces the Growth and Metastasis of Orthotopic Tongue Oral Squamous Cell Carcinomas
Agostini, M., Almeida, L. Y., Bastos, D. C., Ortega, R. M., Moreira, F. S., Seguin, F., Zecchin, K. G., Raposo, H. F., Oliveira, H. C. F., Amoêdo, N. D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1136 · Cited by 131
AN ANTIPHAGE AGENT ISOLATED FROM ASPERGILLUS SP
Hanson, F. R., & Eble, T. E. (1949) · Journal of Bacteriology · doi:10.1128/jb.58.4.527-529.1949 · Cited by 129
Covalent‐Allosteric Kinase Inhibitors
Weisner, J., Gontla, R., Westhuizen, L. V. D., Oeck, S., Ketzer, J., Janning, P., Richters, A., Mühlenberg, T., Fang, Z., Taher, A., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201502142 · Cited by 125
Slow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis : Residence Time and in Vivo Activity
Lu, H., England, K., Ende, C. W. A., Truglio, J. J., Luckner, S. R., Reddy, B. G., Marlenee, N. L., Knudson, S. E., Knudson, D. L., Bowen, R. A., et al. (2009) · ACS Chemical Biology · doi:10.1021/cb800306y · Cited by 111
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
Modjtahedi, H., Cho, B. C., Michel, M. C., & Solca, F. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-0967-3 · Cited by 109
Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
Gridelli, C., Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., & Ciardiello, F. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-840 · Cited by 109
Mechanistic Insights into a Classic Wonder Drug─Aspirin
Lei, J., Zhou, Y., Xie, D., & Zhang, Y. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5112964 · Cited by 104
Fatty Acid Synthase Is a Key Target in Multiple Essential Tumor Functions of Prostate Cancer: Uptake of Radiolabeled Acetate as a Predictor of the Targeted Therapy Outcome
Yoshii, Y., Furukawa, T., Oyama, N., Hasegawa, Y., Kiyono, Y., Nishii, R., Waki, A., Tsuji, A. B., Sogawa, C., Wakizaka, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064570 · Cited by 101
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Goedken, E. R., Argiriadi, M. A., Banach, D. L., Fiamengo, B. A., Foley, S. E., Frank, K. E., George, J. S., Harris, C. M., Hobson, A. D., Ihle, D. C., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.595181 · Cited by 101
Azinomycins A and B, new antitumor antibiotics. II Chemical structures.
YOKOI, K., NAGAOKA, K., & NAKASHIMA, T. (1986) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.34.4554 · Cited by 101
Case histories of peptidomimetics: Progression from peptides to drugs
Adang, A. E. P., Hermkens, P. H. H., Linders, J. T. M., Ottenheijm, H. C. J., & van Staveren, C. J. (1994) · Recueil des Travaux Chimiques des Pays-Bas · doi:10.1002/recl.19941130202 · Cited by 100
Biochemical Mechanisms of New Molecular Entities (NMEs) Approved by United States FDA During 2001-2004: Mechanisms Leading to Optimal Efficacy and Safety
Swinney, D. C. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743093 · Cited by 92
Quantum Chemical-Based Protocol for the Rational Design of Covalent Inhibitors
Schirmeister, T., Kesselring, J., Jung, S., Schneider, T. H., Weickert, A., Becker, J., Lee, W., Bamberger, D., Wich, P. R., Distler, U., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b03052 · Cited by 89
Electrophilic Warhead-Based Design of Compounds Preventing NLRP3 Inflammasome-Dependent Pyroptosis
Cocco, M., Garella, D., Stilo, A. D., Borretto, E., Stevanato, L., Giorgis, M., Marini, E., Fantozzi, R., Miglio, G., & Bertinaria, M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501072b · Cited by 87
How to Triage PAINS-Full Research
Dahlin, J. L., & Walters, M. A. (2015) · Assay and Drug Development Technologies · doi:10.1089/adt.2015.674 · Cited by 85
Medicinal Chemistry Projects Requiring Imaginative Structure-Based Drug Design Methods
Moitessier, N., Pottel, J., Therrien, É., Englebienne, P., Liu, Z., Tomberg, A., & Corbeil, C. R. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00185 · Cited by 78
Discovery and Optimization of Sulfonyl Acrylonitriles as Selective, Covalent Inhibitors of Protein Phosphatase Methylesterase-1
Bachovchin, D. A., Zuhl, A. M., Speers, A. E., Wolfe, M. R., Weerapana, E., Brown, S. J., Rosen, H., & Cravatt, B. F. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200502u · Cited by 71
Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118)
Kim, Y. B., Kopcho, L. M., Kirby, M., Hamann, L. G., Weigelt, C. A., Metzler, W. J., & Marcinkeviciene, J. A. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2005.11.010 · Cited by 69
Recent developments in cathepsin K inhibitor design.
Grabowskal, U., Chambers, T. J., & Shiroo, M. (2005) · PubMed · Cited by 67
Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity
Li, X., Zuo, Y., Tang, G., Wang, Y., Zhou, Y., Wang, X., Guo, T., Xia, M., Ding, N., & Pan, Z. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017762 · Cited by 65
Using Small Molecules To Dissect Mechanisms of Microbial Pathogenesis
Puri, A. W., & Bogyo, M. S. (2009) · ACS Chemical Biology · doi:10.1021/cb9001409 · Cited by 64
Slow tight-binding inhibition of prolyl endopeptidase by benzyloxycarbonyl-prolyl-prolinal
Bakker, A. V., Jung, S., Spencer, R. W., Vinick, F. J., & Faraci, W. S. (1990) · Biochemical Journal · doi:10.1042/bj2710559 · Cited by 59
Virtual Screening and Computational Optimization for the Discovery of Covalent Prolyl Oligopeptidase Inhibitors with Activity in Human Cells
Cesco, S. D., Deslandes, S., Therrien, É., Levan, D., Cueto, M., Schmidt, R., Cantin, L., Mittermaier, A., Juillerat‐Jeanneret, L., & Moitessier, N. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3002839 · Cited by 57
Peptide‐Based Proteasome Inhibitors in Anticancer Drug Design
Micale, N., Scarbaci, K., Troiano, V., Ettari, R., Grasso, S., & Zappalà, M. (2014) · Medicinal Research Reviews · doi:10.1002/med.21312 · Cited by 53
Constrained Peptidomimetics Reveal Detailed Geometric Requirements of Covalent Prolyl Oligopeptidase Inhibitors
Lawandi, J., Toumieux, S., Seyer, V., Campbell, P. D., Thielges, S., Juillerat‐Jeanneret, L., & Moitessier, N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901013a · Cited by 49
On-the-fly QM/MM docking with attracting cavities.
Chaskar, P., Zoete, V., & Röhrig, U. F. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00406 · Cited by 46
Antiepileptic drugs : pharmacology and therapeutics
Ben‐Menachem, E., Eadie, M. J., & Vajda, F. J. E. (1999) · Springer eBooks · Cited by 43
The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents
Oronsky, B. T., Reid, T. R., Knox, S. J., & Scicinski, J. J. (2012) · Translational Oncology · doi:10.1593/tlo.12187 · Cited by 41
A Novel Transition-state Analogue for Lysozyme, 4-O-β-Tri-N-acetylchitotriosyl Moranoline, Provided Evidence Supporting the Covalent Glycosyl-enzyme Intermediate*
Ogata, M., Umemoto, N., Ohnuma, T., Numata, T., Suzuki, A., Usui, T., & Fukamizo, T. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.439281 · Cited by 40
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques
Rojas, R. J., Edmondson, D. E., Almos, T., Scott, R. H., & Massari, M. E. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.063 · Cited by 37
Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization
Post, J. M., Alexander, S., Wang, Y., Vincelette, J., Vergona, R., Kent, L., Bryant, J. A., Sullivan, M. E., Dole, W. P., Morser, J., et al. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.04.009 · Cited by 33
Oxime esters as selective, covalent inhibitors of the serine hydrolase retinoblastoma-binding protein 9 (RBBP9)
Bachovchin, D. A., Wolfe, M. R., Masuda, K. R., Brown, S. J., Spicer, T., Fernández-Vega, V., Chase, P. S., Hodder, P., Rosen, H., & Cravatt, B. F. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.02.011 · Cited by 30
Reversible Covalent Inhibition of eEF‐2K by Carbonitriles
Devkota, A. K., Edupuganti, R., Yan, C., Shi, Y., Jose, J., Wang, Q., Kaoud, T. S., Cho, E. J., Ren, P. Y., & Dalby, K. N. (2014) · ChemBioChem · doi:10.1002/cbic.201402321 · Cited by 30
A mechanism-based inactivator of glycoside hydrolases involving formation of a transient non-classical carbocation
Chakladar, S., Wang, Y., Clark, T., Cheng, L. L., Ko, S., Vocadlo, D. J., & Bennet, A. J. (2014) · Nature Communications · doi:10.1038/ncomms6590 · Cited by 29
A Chemical Genetic Approach for Covalent Inhibition of Analogue-Sensitive Aurora Kinase
Koch, A., Rode, H. B., Richters, A., Rauh, D., & Hauf, S. (2012) · ACS Chemical Biology · doi:10.1021/cb200465c · Cited by 27
On the mechanism of Escherichia coli pyridoxal kinase inhibition by pyridoxal and pyridoxal 5′-phosphate
di Salvo, M. L., Nogués, I., Parroni, A., Tramonti, A., Milano, T., Pascarella, S., & Contestabile, R. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.01.013 · Cited by 27
The discovery and development of boceprevir
Rotella, D. P. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.843525 · Cited by 26
3-Oxo-hexahydro-1H-isoindole-4-carboxylic Acid as a Drug Chiral Bicyclic Scaffold: Structure-Based Design and Preparation of Conformationally Constrained Covalent and Noncovalent Prolyl Oligopeptidase Inhibitors
Mariaule, G., Cesco, S. D., Airaghi, F., Kurian, J., Schiavini, P., Rocheleau, S., Huskić, I., Auclair, K., Mittermaier, A., & Moitessier, N. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01296 · Cited by 25
Automated computational screening of the thiol reactivity of substituted alkenes
Smith, J. M. B., & Rowley, C. N. (2015) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-015-9857-0 · Cited by 24
Time-Dependent Inhibition of Isoprenylcysteine Carboxyl Methyltransferase by Indole-Based Small Molecules
Baron, R., Peterson, Y. K., Otto, J. C., Rudolph, J., & Casey, P. J. (2006) · Biochemistry · doi:10.1021/bi060344n · Cited by 22
The Discovery of Lapatinib (GW572016)
Rusnak, D. W., & Gilmer, T. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0697 · Cited by 21
Differentiating Serine and Cysteine Protease Mechanisms by New Covalent QSAR Descriptors
Shokhen, M., Traube, T., Vijayakumar, S., Hirsch, M., Uritsky, N., & Albeck, A. (2011) · ChemBioChem · doi:10.1002/cbic.201000459 · Cited by 20
Identification of irreversible protein splicing inhibitors as potential anti-TB drugs: insight from hybrid non-covalent/covalent docking virtual screening and molecular dynamics simulations
Blake, L., & Soliman, M. E. S. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0822-y · Cited by 20
Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes
Payne, V. A., Chang, Y., & Loew, G. H. (1999) · Proteins Structure Function and Bioinformatics · doi:10.1002/(sici)1097-0134(19991101)37:2 · Cited by 20
Characterization of C‐Alkyl Amidines as Bioavailable Covalent Reversible Inhibitors of Human DDAH‐1
Lluis, M., Wang, Y., Monzingo, A. F., Fast, W. L., & Robertus, J. D. (2010) · ChemMedChem · doi:10.1002/cmdc.201000392 · Cited by 18
Screening for Dimethylarginine Dimethylaminohydrolase Inhibitors Reveals Ebselen as a Bioavailable Inactivator
Linsky, T. W., Wang, Y., & Fast, W. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml2000824 · Cited by 14
High-Throughput Screening Strategy Identifies Allosteric, Covalent Human D-Amino Acid Oxidase Inhibitor
Terry-Lorenzo, R. T., Masuda, K., Sugao, K., Fang, Q. K., Orsini, M. A., Sacchi, S., & Pollegioni, L. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115600413 · Cited by 12
QSAR classification of metabolic activation of chemicals into covalently reactive species
Liew, C. Y., Pan, C., Tan, A., Ang, K. X. M., & Yap, C. W. (2012) · Molecular Diversity · doi:10.1007/s11030-012-9364-3 · Cited by 11
Nouvelle perspective de traitement dans le cancer bronchique non à petites cellules (CBNPC). Place de l’afatinib : un inhibiteur oral et irréversible de la famille ErbB
Wislez, M., Malka, D., Bennouna, J., Mortier, L., Bensadoun, R., Sicard, J., Dielenseger, P., Rey, J., Moro‐Sibilot, D., & Scotté, F. (2014) · Bulletin du Cancer · doi:10.1684/bdc.2014.1986 · Cited by 10

Flagged first, then by citations

1 of the 127 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Wislez, 2014, A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: an oral and irreversible ErbB family blocker, B Cancer, 101, 647

Sorted by citations

Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology
Gehringer, M., & Laufer, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 772
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
Douangamath, A., Fearon, D., Gehrtz, P., Krojer, T. J., Lukacik, P., Owen, C. D., Resnick, E., Strain-Damerell, C. M., Aimon, A., Ábrányi‐Balogh, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18709-w · Cited by 539
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.006 · Cited by 475
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
Guo, Y., Liu, Y., Hu, N., Yu, D., Zhou, C., Shi, G., Zhang, B., Wei, M., Liu, J., Luo, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00687 · Cited by 376

See all 345

Authors: De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N.
Affiliations: McGill University (CA)
Corresponding author: Moitessier, Nicolas
ORCID: Mittermaier, Anthony K.
Moitessier, Nicolas
Venue: European Journal of Medicinal Chemistry
Publisher: Elsevier BV
Published: 2017-09
Volume: 138
Pages: 96-114
ISSN: 0223-5234 (ISSN-L)
DOI: 10.1016/j.ejmech.2017.06.019
OpenAlex: W2622009965
Cited by: 315
References: 127
Citations by year: 2026: 20 · 2025: 41 · 2024: 30 · 2023: 39 · 2022: 30 · 2021: 46 · 2020: 45 · 2019: 30 · 2018: 28 · 2017: 5
FWCI: 1.76
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: European Journal of Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
Funders: CIHR (MOP-136943)
Topics: Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
Keywords: covalent inhibitors, covalent enzyme inhibitors, drug discovery, lead optimization, reactivity tuning, computer-aided drug design, mechanism of action, target selection, drug safety
MeSH terms: Biological Products, Humans, Kinetics, Quantum Theory, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Covalent inhibitors design and discovery.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks